PARAGON CARE LIMITED(PGC)

The suspension of trading in the securities of Paragon Care Limited will be lifted immediately following the release by PGC of its Appendix 4D and half year accounts for the period ended 31 December 2023 and an announcement regarding the application of Listing Rules 11.1.2 and 11.1.3 to the acquisition of CH2 Holdings Pty Ltd by PGC.

The company releases its PGC-CH2 Merger Presentation.

ParagonCare notified ASX of the Merger in accordance with Listing Rule 11.1 and sought in-principle advice regarding the application of Listing Rules 11.1.2 and 11.1.3. ASX has confirmed that: ParagonCare is not required to seek shareholder approval under Listing Rule 11.1.2; and ParagonCare is not required to meet the requirements in Chapters 1 and 2 of the Listing Rules as if ParagonCare were applying for admission to the official list under Listing Rule 11.1.3. The Board unanimously recommends that ParagonCare shareholders vote in favour of the resolutions to be considered at the general meeting in respect of the Merger, in the absence of a superior proposal and subject to an independent expert concluding that the Merger is fair and reasonable to ParagonCare shareholders.

S&P Dow Jones Indices Announces March 2024 Quarterly Rebalance of the S&P/ASX Indices. ParagonCare was removed from the list of All Ordinaries "“ Effective Prior to the Open on March 18, 2024.

The company releases a notice of proposed issue of securities.

ParagonCare is pleased to announce the proposed merger with CH2, establishing a premier healthcare wholesaler, distributor, and manufacturer. The Merger enables ParagonCare to facilitate expansion into both existing companies' healthcare wholesaling and distribution networks across Australia, and New Zealand and Asia. This transformative merger signals a strategic move to capitalise on and strengthen our combined operational capabilities in rapidly growing markets. Merger highlights: Combined estimated FY24 pro-forma1 revenues of $3.3 billion and EBITDA of $93 million; Broad geographic reach with direct operations in 8 countries across Australia, New Zealand and Asia Pacific region; Significant synergies identified across the business platform; Experienced management team and Board capitalising on growth in these dynamic growing markets; Extensive first-tier partner/supplier network; Cross-selling opportunities across both businesses; Creates a robust framework for both organic and acquisitive growth; Best-in-class logistics, technology and innovation healthcare solution provider; Fully integrated and truly independent supplier; Potential for significant shareholder value creation.

The securities of the company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Friday, 1 March 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Thursday, 29 February 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed.

we understand that on or about this date the company consolidated its shares 1 for 10

ASIC has succeeded in obtaining a pecuniary penalty order and disqualification order in civil penalty proceedings against Mr Ravi Amrit Narain of Bellarine, Victoria. Mr Narain was a former managing director and chief executive officer of Citrofresh International Limited, now known as Paragon Care Limited

name changed from Citrofresh International Limited